Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas.
暂无分享,去创建一个
P. de Paepe | C. de Wolf‐Peeters | M. Stul | R. Achten | G. Verhoef | M. Praet | I. Wlodarska | V. Vanhentenrijk
[1] A. Ng,et al. Diffuse large B-cell lymphoma. , 2007, Seminars in radiation oncology.
[2] Kajia Cao,et al. BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. , 2004, The American journal of pathology.
[3] A. Hagemeijer,et al. Coexistence of BCL1/CCND1 and CMYC aberrations in blastoid mantle cell lymphoma: a rare finding associated with very poor outcome , 2004, Annals of Hematology.
[4] Chung-Che Chang,et al. Immunohistochemical Expression Patterns of Germinal Center and Activation B-cell Markers Correlate With Prognosis in Diffuse Large B-cell Lymphoma , 2004, The American journal of surgical pathology.
[5] L. Staudt,et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.
[6] S. Barrans,et al. The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[7] Emili Montserrat,et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. , 2003, Blood.
[8] L. Staudt,et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.
[9] S. Barrans,et al. Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B‐cell lymphoma , 2002, British journal of haematology.
[10] Ash A. Alizadeh,et al. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. , 2002, Blood.
[11] Martin J S Dyer,et al. Interphase FISH assays for the detection of translocations with breakpoints in immunoglobulin light chain loci , 2002, International journal of cancer.
[12] S. Barrans,et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. , 2002, Blood.
[13] B. Nathwani,et al. Diffuse Large B-cell Lymphoma: A Clinicopathologic Analysis of 444 Cases Classified According to the Updated Kiel Classification , 2002, Leukemia & lymphoma.
[14] Todd,et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning , 2002, Nature Medicine.
[15] K. Ohshima,et al. CD10 and Bcl10 expression in diffuse large B‐cell lymphoma: CD10 is a marker of improved prognosis , 2001, Histopathology.
[16] H. Ohno,et al. Nonimmunoglobulin (non-Ig)/BCL6gene fusion in diffuse large B-cell lymphoma results in worse prognosis than Ig/BCL6 , 2000 .
[17] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[18] J Hermans,et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. , 1998, Blood.
[19] F. Mandelli,et al. Pathogenetic and clinical implications of Bcl‐6 and Bcl‐2 gene configuration in nodal diffuse large B‐cell lymphomas , 1997, The Journal of pathology.
[20] S. Fukuhara,et al. Significance of rearrangement of the BCL6 gene in B-cell lymphoid neoplasms. , 1997, Leukemia & lymphoma.
[21] K. Franssila,et al. BCL2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma. , 1997, Blood.
[22] J C Reed,et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. , 1997, Blood.
[23] M. Engelhard,et al. Subclassification of diffuse large B-cell lymphomas according to the Kiel classification: distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factor. , 1997, Blood.
[24] D C Linch,et al. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study. , 1996, Blood.
[25] S. Pittaluga,et al. Fluorescence in situ hybridization identifies new chromosomal changes involving 3q27 in non‐Hodgkin's lymphomas with BCL6/LAZ3 rearrangement , 1995, Genes, chromosomes & cancer.
[26] M. Ladanyi,et al. Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma. , 1994, The New England journal of medicine.
[27] Atkins Cd. A predictive model for non-Hodgkin's lymphoma. , 1994 .
[28] S. Poppema,et al. Clinical significance of bcl-2-MBR gene rearrangement and protein expression in diffuse large-cell non-Hodgkin's lymphoma: an analysis of 83 cases. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] N. Harris,et al. bcl‐2 Rearrangements in de novo diffuse large cell lymphoma. Association with distinctive clinical features , 1993, Cancer.
[30] M. Oken,et al. bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma. , 1989, The New England journal of medicine.